Danaher Co. (NYSE:DHR) Shares Sold by 9258 Wealth Management LLC

9258 Wealth Management LLC decreased its holdings in Danaher Co. (NYSE:DHR) by 4.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,447 shares of the conglomerate’s stock after selling 65 shares during the period. 9258 Wealth Management LLC’s holdings in Danaher were worth $362,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Gilbert & Cook Inc. increased its holdings in Danaher by 4.9% in the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock valued at $423,000 after purchasing an additional 86 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Danaher by 1.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after buying an additional 43 shares in the last quarter. Accretive Wealth Partners LLC raised its holdings in shares of Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after buying an additional 414 shares during the period. Wealthcare Advisory Partners LLC lifted its position in Danaher by 8.8% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 1,649 shares of the conglomerate’s stock worth $382,000 after acquiring an additional 134 shares in the last quarter. Finally, Gryphon Financial Partners LLC boosted its holdings in Danaher by 19.1% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock worth $675,000 after acquiring an additional 468 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.1 %

DHR stock opened at $264.80 on Friday. The firm has a fifty day moving average price of $260.98 and a two-hundred day moving average price of $255.61. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The firm has a market cap of $196.13 billion, a price-to-earnings ratio of 44.88, a PEG ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the business earned $2.05 earnings per share. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. Research analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on DHR. Evercore ISI dropped their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Leerink Partners boosted their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Stifel Nicolaus raised their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $278.94.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.